GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE
Clinical trials for GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE explained in plain language.
Never miss a new study
Get alerted when new GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE trials appear
Sign up with your email to follow new studies for GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for brain cancer patients: experimental combo enters trials
Disease control Recruiting nowThis study tests a new drug (Debio 0123) combined with standard chemotherapy (temozolomide) and sometimes radiation in adults with glioblastoma, an aggressive brain cancer. The goal is to find the safest dose and see if the combination helps people live longer. About 116 particip…
Matched conditions: GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE
Phase: PHASE1, PHASE2 • Sponsor: Debiopharm International SA • Aim: Disease control
Last updated Jun 22, 2026 12:04 UTC
-
New drug targets deadly brain cancer in early trial
Disease control Recruiting nowThis study tests an experimental drug called LMP744 in 40 adults whose glioblastoma (a serious brain cancer) has returned after standard treatment. The drug is given through a vein for 5 days each month for up to a year. The goal is to see if it can shrink tumors or slow their gr…
Matched conditions: GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Disease control
Last updated Jun 17, 2026 12:10 UTC